Bio-Rad Laboratories, Inc. $BIO Shares Sold by Fisher Asset Management LLC

Fisher Asset Management LLC lessened its stake in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) by 3.1% in the 3rd quarter, Holdings Channel.com reports. The firm owned 133,465 shares of the medical research company’s stock after selling 4,277 shares during the quarter. Fisher Asset Management LLC’s holdings in Bio-Rad Laboratories were worth $37,422,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the company. Quent Capital LLC purchased a new position in Bio-Rad Laboratories during the 3rd quarter worth $25,000. Farther Finance Advisors LLC increased its stake in shares of Bio-Rad Laboratories by 52.9% during the third quarter. Farther Finance Advisors LLC now owns 104 shares of the medical research company’s stock worth $29,000 after acquiring an additional 36 shares during the period. Geneos Wealth Management Inc. raised its holdings in Bio-Rad Laboratories by 115.2% during the second quarter. Geneos Wealth Management Inc. now owns 142 shares of the medical research company’s stock worth $34,000 after purchasing an additional 76 shares in the last quarter. CWM LLC lifted its position in Bio-Rad Laboratories by 82.0% in the third quarter. CWM LLC now owns 202 shares of the medical research company’s stock valued at $57,000 after purchasing an additional 91 shares during the period. Finally, UMB Bank n.a. boosted its holdings in Bio-Rad Laboratories by 24.0% in the 3rd quarter. UMB Bank n.a. now owns 207 shares of the medical research company’s stock valued at $58,000 after purchasing an additional 40 shares in the last quarter. 65.24% of the stock is currently owned by hedge funds and other institutional investors.

Bio-Rad Laboratories Price Performance

Shares of NYSE:BIO opened at $280.73 on Wednesday. The firm has a market capitalization of $7.58 billion, a price-to-earnings ratio of 10.06 and a beta of 1.18. The company has a debt-to-equity ratio of 0.16, a current ratio of 5.62 and a quick ratio of 4.19. The business’s 50 day simple moving average is $297.25 and its 200-day simple moving average is $301.46. Bio-Rad Laboratories, Inc. has a 12 month low of $211.43 and a 12 month high of $343.12.

Bio-Rad Laboratories (NYSE:BIO) last released its quarterly earnings data on Thursday, February 12th. The medical research company reported $2.51 earnings per share for the quarter, missing the consensus estimate of $2.57 by ($0.06). The firm had revenue of $693.20 million during the quarter, compared to analysts’ expectations of $694.64 million. Bio-Rad Laboratories had a net margin of 29.42% and a return on equity of 3.86%. The business’s revenue for the quarter was up 3.9% on a year-over-year basis. During the same period in the previous year, the business earned $2.90 earnings per share. As a group, equities analysts forecast that Bio-Rad Laboratories, Inc. will post 10.81 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on BIO. Weiss Ratings reissued a “sell (d-)” rating on shares of Bio-Rad Laboratories in a research note on Monday, December 29th. Wall Street Zen lowered Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a report on Saturday, February 14th. Three investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Bio-Rad Laboratories currently has an average rating of “Hold” and a consensus target price of $358.50.

Bio-Rad Laboratories Profile

Bio-Rad Laboratories, Inc is a global provider of life science research and clinical diagnostic products. The company operates through two primary business segments: Life Science and Clinical Diagnostics. Within the Life Science segment, Bio-Rad offers instruments, reagents and consumables for protein analysis, cell biology, gene expression and other molecular biology applications. The Clinical Diagnostics segment supplies quality control products, blood-typing reagents and instruments, and molecular diagnostic assays used in blood screening, infectious disease testing and routine clinical laboratories.

Founded in 1952 by David and Alice Schwartz and headquartered in Hercules, California, Bio-Rad has grown its footprint across the Americas, Europe, Asia-Pacific and other regions.